{"filing":{"accession_number":"0001104659-26-095424","cik":"0001070081","ticker":"PTCT","company_name":"PTC THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-12","primary_document":"tmb-20260812x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1070081/000110465926095424/tmb-20260812x8k.htm"},"events":[{"id":27449,"run_id":25024,"accession_number":"0001104659-26-095424","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"PTC Therapeutics announced its selection as the winning bidder to acquire ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction. The transaction includes $111 million upfront and up to $100 million in contingent milestone payments, with expected closing in late Q3 or early Q4 2026, subject to bankruptcy court approval and customary closing conditions.","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29001,"accession_number":"0001104659-26-095424","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"PTC Therapeutics announced it was selected as the winning bidder to acquire ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction. The transaction terms include $111 million upfront and up to $100 million in contingent milestone payments. This is a material acquisition of a late-stage product candidate that directly expands PTC's rare disease portfolio and is expected to close in late Q3 or early Q4 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:02:14.829225+00:00","company_name":"","ticker":null,"filing_date":""},{"id":29002,"accession_number":"0001104659-26-095424","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"PTC Therapeutics announced its selection as the winning bidder to acquire ST-920, a BLA-stage gene therapy program, from Sangamo Therapeutics in a competitive bankruptcy auction. The transaction involves $111 million upfront and up to $100 million in contingent milestone payments, with expected closing in late Q3 or early Q4 2026. This is a material acquisition of a late-stage therapeutic asset that expands PTC's rare disease portfolio and is subject to bankruptcy court approval and other customary closing conditions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:02:14.829225+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29001,"accession_number":"0001104659-26-095424","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"PTC Therapeutics announced it was selected as the winning bidder to acquire ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction. The transaction terms include $111 million upfront and up to $100 million in contingent milestone payments. This is a material acquisition of a late-stage product candidate that directly expands PTC's rare disease portfolio and is expected to close in late Q3 or early Q4 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:02:14.829225+00:00","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-08-13"},{"id":29002,"accession_number":"0001104659-26-095424","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"PTC Therapeutics announced its selection as the winning bidder to acquire ST-920, a BLA-stage gene therapy program, from Sangamo Therapeutics in a competitive bankruptcy auction. The transaction involves $111 million upfront and up to $100 million in contingent milestone payments, with expected closing in late Q3 or early Q4 2026. This is a material acquisition of a late-stage therapeutic asset that expands PTC's rare disease portfolio and is subject to bankruptcy court approval and other customary closing conditions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:02:14.829225+00:00","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-08-13"}]}